Yan Wang
Los Angeles
Education
Sc.D., biostatistics and environmental health, and M.S., environmental health, Harvard T.H. Chan School of Public Health; B.S., environmental science, and B.Econ, economics, Peking University
Summary of Experience
Dr. Wang is experienced in providing consulting services to life sciences companies, with a focus on real-world evidence (RWE) generation and health economics and outcomes research (HEOR). His expertise encompasses such topics as the analysis of clinical trial data and real-world databases, indirect treatment comparisons, health economics modeling, support for health technology assessment (HTA) submissions, surveys, and chart reviews. Dr. Wang has provided support for pharmaceutical products in different phases of development and contributed to studies in a diverse range of therapeutic areas, including cardiovascular disease, dermatology, hematology, immunology, infectious disease, metabolic disorders, neurology, oncology, and rheumatology. His work has been published in peer-reviewed journals and presented at clinical and economic research conferences.
Selected Publishing
-
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Advances in Therapy, 2024
2024Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, Betts KA, Wang Y, Irvine AD, Panaccione R
-
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research, 2024
2024Mahon R, Tiwari S, Koch M, Ferraris M, Betts KA, Wang Y, Gao S, Proot P
-
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Cancer Immunology, Immunotherapy, 2022
2022Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN
-
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial
Journal of Medical Economics, 2022
2022Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP
-
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Dermatology and Therapy, 2022
2022Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L
-
Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit
Clinical Therapeutics, 2022
2022Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP
-
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Dermatology and Therapy, 2021
2021Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M
-
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Journal of the American Academy of Dermatology, 2021
2021Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW
-
Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations
Kidney International Reports, 2020
2020
News
-
April 11, 2024
-
April 4, 2024
-
March 2, 2023
-
June 4, 2021